President Trump And I Take The Same Drugs — Except One
An aging writer discovers there are worse things than going bald after examining the side effects of a popular hair loss drug purportedly used by President Donald Trump.
The independent source for health policy research, polling, and news.
1,161 - 1,180 of 1,298 Results
An aging writer discovers there are worse things than going bald after examining the side effects of a popular hair loss drug purportedly used by President Donald Trump.
Aging adults with complex needs can get special assistance from doctors trained as geriatricians.
Some terminal patients, typically high-dose opioid users, who choose to end their lives have taken many hours, even days, to die.
The woman set to run the federal Centers for Medicare & Medicaid Services told senators last week that maternity coverage should be optional in individual and small group plans. But other services could also be left on the cutting room floor.
A drug from Marathon Pharmaceuticals has ignited a firestorm on Capitol Hill and beyond. What makes it different than the $750,000 drug that came before it?
A study shows some emergency physicians wrote far more opioid prescriptions and Medicare patients who saw those doctors were more likely to still be taking the addictive painkillers months later.
Former FDA Commissioner Dr. Robert Califf shares his views about drug approvals, regulations and safety concerns after stepping down from the giant agency.
After hearing complaints about its high price, Marathon Pharmaceuticals is pausing the launch of an $89,000 drug for a rare disease.
Citing a Kaiser Health News investigation, Senate Judiciary Committee Chairman Chuck Grassley vows to examine the orphan drug program and possible fixes.
The FDA has approved dozens of new cancer medications in recent years, but few offer the benefits that patients seek.
Prescription pain pills are strong sellers in this southeastern Kentucky region that’s long struggled with high rates of joblessness and poor health.
Kaiser Health News reporter Shefali Luthra discusses the controversy surrounding Kaleo, a company that makes a life-saving auto-injector for opioid drug overdoses on Weekend Edition.
Luke Whitbeck’s life was saved by a rare disease drug, but it costs $300,000 a year.
Despite questions about Lupron’s lasting side effects and minimal study into its safety, the FDA sped approval of the drug to market. Years later, some young women are still living with the consequences.
An expert geriatrician says the benefits for the patient, such as alleviating pain and maintaining independence, must be weighed against the possible risks. Her motto: ‘start low and go slow.’
Alzheimer's researchers hold onto hope after another promising trial ends in disappointment.
Wood, who chairs the Assembly Health Committee, lays out his priorities for 2017.
The device, known as Evzio, administers just enough naloxone to stabilize someone who has overdosed on drugs. But its manufacturer, Kaleo, may be positioning itself to find profits in a dire health care crisis.
African-American women are more likely to be infected with HIV than other women. So the District of Columbia is launching an effort to inform them about PrEP, medication that can reduce their risk.
The designation, which is made by the Food and Drug Administration, allows drugmakers to claim seven years of market exclusivity.
© 2026 KFF